Mobidiag announces the launch of Automobi Molecular Diagnostics

Monday, June 03, 2019

Mobidiag Ltd., a commercial molecular diagnostics company committed to fighting the spread of antimicrobial resistance, announced today the launch of Automobi Molecular Diagnostics Co., Ltd ( 'Automobi'), the joint venture ('JV') between Mobidiag and Autobio Diagnostics ('Autobio'), one of the leading clinical diagnostic companies in China. Automobi is responsible for the marketing of the Novodiag ® platform and for the analysis of certain infectious diseases in the Greater China area.

The initial activities of Automobi will include the registration of the Novodiag ® platform and the first analyzes at the National Medical Products Administration (NMPA, formerly CFDA).

The original text of this announcement, written in the source language, is the official version that is authentic. The translations are offered solely for the reader's convenience and must refer to the text in the original language, which is the only legally valid one.

Contacts
Mobidiag Ltd.
Dorothee Allard, Marketing Communications Manager
Tel .: +33 (0) 1 55 25 17 13
marketing@mobidiag.com

Autobio Diagnostics Co., Ltd.
Iris Li
Tel.:+86 371 67985313
info@autobio-diagnostics.com

Lynx Financial (Financial Advisor in China)
Flora Gao, Partner
Tel .: +86 177 01610979
lynx@lynx-financial.com

Consilium Strategic Communications
Chris Gardner, Matthew Neal, Chris Welsh
Tel .: +44 (0) 203 709 5700
mobidiag@consilium-comms.com